Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Will Revise Investigator Disqualification Regs In Response To GAO Report

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency will revise its regulations to prevent clinical investigators who are disqualified from running trials for one product type to continue leading studies for other FDA-regulated categories.
Advertisement

Related Content

FDA’s Wayback Machine: Clinical Investigator Disqualifications Could Trigger Wide-Ranging Audits
Informed Consent Guidance Allows Discussion Of Specimen "Donation"
Informed Consent Guidance Allows Discussion Of Specimen "Donation"
Clinical Researcher Debarments Proceeding Slowly, Despite FDA Promises Of Reform
Clinical Researcher Debarments Proceeding Slowly, Despite FDA Promises Of Reform
FDA Will Move Faster To Ban Bad Actors From Clinical Trials
FDA Will Move Faster To Ban Bad Actors From Clinical Trials

Topics

Advertisement
UsernamePublicRestriction

Register

PS068781

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel